The drugs taken for lung infections need to be combined with the patient’s age, the disease that preceded the lung infection, the location of the infection, and the possible causative organisms to choose the appropriate antibiotic. Choosing an effective antibiotic at the start of treatment can control the infection as soon as possible. For patients with pulmonary infections who have not used antibiotics within 3 months and who do not have underlying cardiopulmonary disease or risk factors, common pathogens include Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila, penicillins, first-generation cephalosporins, macrolides, and quinolones can be administered. For patients with underlying cardiopulmonary disease or lung infections with risk factors, broad-spectrum penicillins, endocannabinoid inhibitors, and second- and third-generation cephalosporins can be taken. The resistance rate of Streptococcus pneumoniae to macrolides in China is generally greater than 60%, and it mostly shows a high level of resistance. Therefore, macrolides alone should not be used in patients suspected of Streptococcus pneumoniae infection, but macrolides still have good effects against Mycoplasma pneumoniae and Chlamydia pneumoniae. In summary, penicillins, first-generation cephalosporins, macrolides, and fluoroquinolones can be used in patients with previously healthy pulmonary infections without risk factors for drug-resistant organisms. Patients with slightly more severe disease and risk factors for drug-resistant bacteria can use broad-spectrum penicillins, second- and third-generation cephalosporins, etc.